Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Crossref DOI link: https://doi.org/10.1007/s00125-015-3795-1
Published Online: 2015-11-17
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nauck, Michael A.
Stewart, Murray W.
Perkins, Christopher
Jones-Leone, Angela
Yang, Fred
Perry, Caroline
Reinhardt, Rickey R.
Rendell, Marc
Funding for this research was provided by:
GlaxoSmithKline
License valid from 2015-11-17